Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

The introduction of monoclonal antibodies (mAbs) to the treatment of inflammatory bowel disease (IBD) was an important medical milestone. MAbs have been demonstrated as safe and efficacious treatments of IBD. However, a large percentage of patients either fail to respond initially or lose response t...

Descripción completa

Detalles Bibliográficos
Autores principales: Strik, Anne S., Wang, Yow-Ming C., Ruff, Laura E., Yashar, William, Messmer, Bradley T., Mould, Diane R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364290/
https://www.ncbi.nlm.nih.gov/pubmed/30187153
http://dx.doi.org/10.1208/s12248-018-0257-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8364290/
https://www.ncbi.nlm.nih.gov/pubmed/30187153
http://dx.doi.org/10.1208/s12248-018-0257-y

Ejemplares similares